Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Finance Group's New CEO Will Put More Cash To Work Internationally

Executive Summary

Healthcare banking veteran, Kasim Kutay, who last month took over as CEO of Novo A/S – a $57bn holding and investment group with a focus on life sciences but a broad setup for all levels of capital provision from seed investment, venture capital to larger, long term investments – talks to Scrip about the challenges for commercialization strategies on the back of the recent wave of R&D productivity and the ongoing uptick for innovation in drug development.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts